SGLT2 INHIBITOR TREATMENT MAY ENHANCE KIDNEY OXYGENATION AND ATTENUATE HIF1A EXPRESSION IN YOUNG PERSONS WITH TYPE 2 DIABETES

Chronic Kidney Disease, Hypertension, Diabetes and CVD

Diabetic Kidney Disease, Drugs and Treatments

 

 

 

 

Nairms, V.(1)*;Schaub, J.(2);Alakwaa, F.(2);Mccown, P.(2);Naik, A.(3);Ladd, P.(4);Harned, R.(4);Looker, H.(5);Pottumarthi, P.(6);Luping, L.(6);Pyle, L.(7);Brosius, F.C.(8);Nelson, R.(5);Kretzler, M.(2);Bjornstad, P.(9);

(1)University Of Michigan Medical Center, Internal Medicine-Nephrology, Ann Arbor, United States;(2)University Of Michigan Medical Center, Nephrology, Ann Arbor, United States;(3)University Of Michigan Medical Center, Internal Medicine, Ann Arbor, United States;(4)University Of Colorado School Of Medicine, Radiology, Aurora, United States;(5)National Institute Of Diabetes And Digestive And Kidney Diseases, Chronic Kidney Disease Section, Phoenix, United States;(6)Northshore University Healthsystem, Radiology, Evanston, United States;(7)Children'S Hospital Colorado, Biostatistics, Aurora, United States;(8)The University Of Arizona College Of Medicine Tucson, Nephrology, Tucson, United States;(9)University Of Colorado School Of Medicine, Pediatrics/Medicine, Aurora, United States;